HealthTech AI Archived

Why does no GLP-1 dose fit someone between the trial cohorts?

Tirzepatide and semaglutide doses jump in big steps. Anyone whose tolerance sits between 5 mg and 7.5 mg cycles through nausea, plateaus, and unauthorized self-titration. Telehealth clinicians won't deviate from the label.

Who has it: GLP-1 patients on Zepbound, Wegovy, Mounjaro, Ozempic who can't tolerate the next labelled dose.

Patients describe a lower dose that stops working while the next step up causes harsh side effects, and say telehealth prescribers will not consider anything in between.

Our summary of a complaint that recurs in public posts, not a quote. Nobody submitted it to Real Problem AI.

Seen in: r/Mounjaro, r/Zepbound, r/Ozempic dose-titration megathreads with 10K+ comments through 2025 and 2026.

Why it is archived

Swapped out in AI-tool-builder content refresh (2026-08-26): generic vertical problem replaced by a more current, builder-relevant one.

Scoring breakdown

8.0/ 10

Problem Severity8

Feasibility today7

Market Signal9

Competition Gap8

Existing players

Telehealth clinics (Ro, Hims, Sequence) · Stick to label, won't customise between doses
Compounded pharmacies · Mostly delisted post-FDA shortage end, legally squeezed
Reddit DIY titration spreadsheets · Best resource patients have today, unsupervised

What they are missing

An evidence-curated micro-titration coach: log side-effect patterns, weight, food intake, suggest the dose the patient's GP can actually prescribe under shared-decision-making, with the citations attached. Connects to a real prescriber for the off-label step, not a vending machine.

Stack hint

01Symptom and dose journal with side-effect taxonomy

02Curated trial and registry data, citation-first responses

03Shared-decision-making PDF the patient walks into their GP's office with

04Prescriber network for off-label dosing where allowed

#H19 · Canonical URL: https://www.realproblem.ai/archive/why-does-no-glp1-dose-fit-someone-between-the-trial-cohorts